Becton Dickinson & Co (BDX)
233.45
+0.30
(+0.13%)
USD |
NYSE |
Apr 19, 15:52
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 67.44B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -6.66% |
| Valuation | |
| PE Ratio | 55.32 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 3.472 |
| Price to Book Value | 2.662 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.95 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.6359 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 29.62% |
Profile
| Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures pre-filled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (27% of 2023 revenue) and BD Interventional (24%) account for the remainder. International revenue accounts for 43% of the company's business. |
| URL | https://www.bd.com |
| Investor Relations URL | https://investors.bd.com/ |
| HQ State/Province | New Jersey |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Large Cap/Blend |
| Next Earnings Release | May. 02, 2024 |
| Last Earnings Release | Feb. 01, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Mar. 07, 2024 |
Ratings
Profile
| Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures pre-filled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (27% of 2023 revenue) and BD Interventional (24%) account for the remainder. International revenue accounts for 43% of the company's business. |
| URL | https://www.bd.com |
| Investor Relations URL | https://investors.bd.com/ |
| HQ State/Province | New Jersey |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Large Cap/Blend |
| Next Earnings Release | May. 02, 2024 |
| Last Earnings Release | Feb. 01, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Mar. 07, 2024 |